Juan Jesús Gómez Reino Carnota-rekin lankidetzan egindako argitalpenak (8)

2021

  1. Update of the Position Paper of the Spanish Society of Rheumatology on Biosimilar Drugs

    Reumatologia Clinica, Vol. 17, Núm. 3, pp. 160-169

2020

  1. Influence of age on the occurrence of adverse events in rheumatic patients at the onset of biological treatment: Data from the BIOBADASER III register

    Arthritis Research and Therapy, Vol. 22, Núm. 1

2019

  1. Factors associated with long-term retention of treatment with golimumab in a real-world setting: an analysis of the Spanish BIOBADASER registry

    Rheumatology International, Vol. 39, Núm. 3, pp. 509-515

  2. Objectives and methodology of BIOBADASER phase III

    Reumatologia Clinica, Vol. 15, Núm. 4, pp. 229-236

2018

  1. Persistence and adverse events of biological treatment in adult patients with juvenile idiopathic arthritis: Results from BIOBADASER

    Arthritis Research and Therapy, Vol. 20, Núm. 1

  2. Status of Rheumatology in Spain in 2017: 2.0 Rheumatologists per 100,000 Population

    Reumatologia Clinica

2010

  1. Recommendations for the management of influenza A (H1N1) in rheumatic patients with immunosuppression

    Reumatologia Clinica, Vol. 6, Núm. 1, pp. 63-68

1994

  1. Nontropical pyomyositis in adults

    Seminars in Arthritis and Rheumatism, Vol. 23, Núm. 6, pp. 396-405